CDC pushes for prioritized contact tracing; urban hospitals struggle to keep up with influx of rural patients; Texas and Louisiana can cut Medicaid funding to Planned Parenthood.
Due to sharp increases in coronavirus disease 2019 (COVID-19) cases, the CDC advised overwhelmed local health officials to triage contact tracing efforts, Politico reported. New guidance from the CDC states that health departments ought to prioritize which cases to investigate and which contacts to trace. Specifically, tracers should contact those who tested positive within the last 6 days, members of their immediate household, the elderly and patients with medical conditions, and individuals living or working in congregate settings. The agency also recommended against contacting infected people more than 2 weeks out from their positive test as it is likely too late to prevent them from spreading the virus.
The sickest patients with COVID-19 residing in rural areas of America are being sent to cities and putting a strain on hospitals, according to Kaiser Health News. For example, although Kansas City has a mask mandate in place, many smaller communities around the city nearby do not. Rural counties in Kansas and Missouri have seen some of the highest COVID-19 rates in the country in the past few months. Roughly 3 in 4 counties in these states do not have a single intensive care unit bed, meaning critically ill patients get relocated to city hospitals. In one hospital in Kansas City, two-thirds of patients coming from rural areas needed intensive care and stayed in the hospital for an average of 2 weeks.
A federal appeals court ruled Texas and Louisiana can cut Medicaid funding to Planned Parenthood clinics, the Associated Press reported. Supporters of the ruling, handed down by the 5th US Circuit Court of Appeals in New Orleans, are opponents of federal funding going toward legal abortion, while opponents say the ruling will affect a variety of non-abortion health services for low-income women. The ruling reversed a decision blocking Texas from enforcing its ban on Medicaid funding of Planned Parenthood. The new ruling is expected to go to the Supreme Court. Advocates for women’s health argue the move will reduce access to women seeking cancer screenings, birth control, and other health services even in states where clinics do not perform abortions.
Standard Criteria for Loss of Ambulation Needed in DMD
April 19th 2024A recent study suggests the differences between ambulation definitions for patients with Duchenne muscular dystrophy (DMD) can impact the identification of ambulant vs nonambulant individuals, and standard criteria across settings are needed.
Read More
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
February 13th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen
An Overview of Health Care and Pharmaceutical Trends, 2023-2024
April 19th 2024Douglas M. Long, BA, MBA, was featured as the keynote speaker on the closing day of The Academy of Managed Care Pharmacy 2024 annual meeting, with a session dedicated to surveying the health care and pharmaceutical trends of the last year.
Read More
Drs Raymond Thertulien, Joseph Mikhael on Racial Disparities in Multiple Myeloma Care Access
December 28th 2023In the wake of the 2023 American Society of Hematology Annual Meeting and Exposition, Raymond Thertulien, MD, PhD, of Novant Health, and Joseph Mikhael, MD, MEd, FRCPC, FACP, chief medical officer of the International Myeloma Foundation, discussed health equity research highlights from the meeting and drivers of racial disparities in multiple myeloma outcomes.
Listen
Real-World Study Reveals Key Insights Into DLBCL Treatment Patterns, Outcomes
April 18th 2024A recent study offers valuable insights into the characteristics, treatment patterns, and outcomes of diffuse large B-cell lymphoma (DLBCL) in patients across different lines of therapy, providing a look into the landscape of DLBCL management.
Read More